About knowledge translation & commercialization
About knowledge translation
At CIHR, knowledge translation (KT) is defined as a dynamic and iterative process that includes synthesis, dissemination, exchange and ethically-sound application of knowledge to improve the health of Canadians, provide more effective health services and products and strengthen the health care system.
This process takes place within a complex system of interactions between researchers and knowledge users which may vary in intensity, complexity and level of engagement depending on the nature of the research and the findings as well as the needs of the particular knowledge user.
For more information about knowledge translation, please see:
The objective of CIHR is to excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians; more effective services and products; and a strengthened Canadian health care system. Harnessing our investments in health research is key to improving the health of our citizens, building sustainable, evidence-based, leading-edge health care and public health systems, and developing the transformative new technologies of tomorrow. To facilitate this process, CIHR has developed a dynamic and innovative strategy for the commercialization of health research, based on four thematic drivers: Research, Talent, Capital and Linkages.
CIHR currently offers a suite of commercialization initiatives that encourage the capacity of universities and teaching hospitals to interact with partners responsible for delivering the benefits of health research. It offers vehicles to support seed funding for pre-competitive research development of projects deemed to possess commercial potential, provides opportunities for entrepreneurial training and provides support for technology transfer process elements and infrastructure.
As the Government of Canada's agency for health research, CIHR will work with all partners in a concerted effort to move research more effectively through the marketplace to caretakers and ultimately patients that will benefit from innovations and discoveries. Through its focus on commercialization, CIHR is playing a central role in encouraging innovation that will result in solutions to the health problems that concern Canadians most as well as contribute to economic growth, investment and high-quality jobs.
CIHR partners with leading R&D corporations
CIHR has partnership agreements with 12 of Canada's Top 100 corporate spenders in R&D, according to national rankings recently published by Re$earch Money. We are proud to collaborate with leaders in the pharmaceutical and biotechnology industries to put research results in the hands of patients.
|Rank||Company||Year Established Partnership|
|15||Pfizer Canada Inc.||2007|
|21||Novartis Pharmaceuticals Canada Inc.||2007|
|22||Merck Frosst Canada Inc.||2008|
|23||AstraZeneca Canada Inc.||2007|
|91||Vifor Pharma, Aspreva International Ltd||2008|
|98||Bioniche Life Sciences Inc.||2007|
Supplemental content (right column)